Literature DB >> 8016797

Ultrasound guided pericardial drainage and intrapericardial instillation of mitomycin C for malignant pericardial effusion.

L N Lee1, P C Yang, D B Chang, C J Yu, J C Ko, Y S Liaw, R G Wu, K T Luh.   

Abstract

BACKGROUND: Conservative treatment of malignant pericardial effusion by intrapericardial instillation of a sclerosing agent may be an alternative to surgery.
METHODS: Twenty patients with malignant pericardial effusion were treated by ultrasound guided pericardiocentesis and the intrapericardial instillation of mitomycin C.
RESULTS: Mitomycin C was effective in controlling the pericardial effusion in 70% of patients without causing side effects, except for pericardial constriction seven months later in one subject.
CONCLUSIONS: Ultrasound guided intrapericardial instillation of mitomycin C is a suitable alternative in the management of malignant pericardial effusion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016797      PMCID: PMC474956          DOI: 10.1136/thx.49.6.594

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  9 in total

1.  Secondary malignant tumors of the pericardium.

Authors:  D L THURBER; J E EDWARDS; R W ACHOR
Journal:  Circulation       Date:  1962-08       Impact factor: 29.690

2.  Intrapericardial OK-432 instillation for the management of malignant pericardial effusion.

Authors:  T Imamura; K Tamura; M Takenaga; Y Nagatomo; T Ishikawa; S Nakagawa
Journal:  Cancer       Date:  1991-07-15       Impact factor: 6.860

3.  Intrapericardial installation of bleomycin in malignant pericardial effusion.

Authors:  E R Maher; R Buckman
Journal:  Am Heart J       Date:  1986-03       Impact factor: 4.749

Review 4.  Neoplastic cardiac tamponade.

Authors:  A Theologides
Journal:  Semin Oncol       Date:  1978-06       Impact factor: 4.929

5.  Catheter drainage of the pericardium. Practical method to maintain long-term patency.

Authors:  A K Patel; P K Kosolcharoen; M Nallasivan; G M Kroncke; J H Thomsen
Journal:  Chest       Date:  1987-12       Impact factor: 9.410

6.  Conservative management of malignant pericardial effusion.

Authors:  F E Smith; M Lane; P T Hudgins
Journal:  Cancer       Date:  1974-01       Impact factor: 6.860

7.  Intrapericardial tetracycline sclerosis in the treatment of malignant pericardial effusion: an analysis of thirty-three cases.

Authors:  S Davis; P Rambotti; F Grignani
Journal:  J Clin Oncol       Date:  1984-06       Impact factor: 44.544

8.  Intrapericardial instillation of platin in malignant pericardial effusion.

Authors:  M V Fiorentino; O Daniele; P Morandi; S M Aversa; C Ghiotto; A Paccagnella; A Fornasiero
Journal:  Cancer       Date:  1988-11-01       Impact factor: 6.860

9.  Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial.

Authors:  K T Luh; P C Yang; S H Kuo; D B Chang; C J Yu; L N Lee
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

  9 in total
  4 in total

1.  Case report: cardiac tamponade resembling an acute myocardial infarction as the initial manifestation of metastatic pericardial adenocarcinoma.

Authors:  Scott A Scheinin; Jose Sosa-Herrera
Journal:  Methodist Debakey Cardiovasc J       Date:  2014 Apr-Jun

2.  Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer.

Authors:  T Moriya; Y Takiguchi; H Tabeta; R Watanabe; H Kimura; K Nagao; T Kuriyama
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

3.  [Clinical Observation of Gefitinib with Pericardial Perfusion for 
Advanced Non-small Cell Lung Cancer].

Authors:  Xiaomeng Wang; Jin Chen; Jiaqi Yao; Renhua Guo
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-01-20

4.  Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study.

Authors:  Mie Kotake; Hisao Imai; Kyoichi Kaira; Tomomi Fujisawa; Yasuhiro Yanagita; Koichi Minato
Journal:  Cancer Chemother Pharmacol       Date:  2019-06-27       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.